News Daily News New USPSTF Guidelines Recommend Statins in ‘Appropriately Selected’ Primary-Prevention Patients Michael O'Riordan November 13, 2016
News Daily News High-Intensity Statin Therapy Offers Survival Benefit Over Moderate-Intensity Statins in CVD Patients Michael O'Riordan November 10, 2016
News Daily News Pharmacist Management of High Cholesterol Gets More Patients to Goal, Lowers LDL Levels: RxACT Michael O'Riordan September 29, 2016
News Daily News Many Guidelines, Mixed Consensus: Different CVD Risk Guidelines Cause Confusion in Practice Michael O'Riordan September 16, 2016
News Daily News Nearly 40% of Diabetic Patients Not Treated With Statins: PINNACLE Registry Michael O'Riordan September 13, 2016
News Conference News ESC 2016 Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER Michael O'Riordan August 30, 2016
News Conference News ESC 2016 Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say Michael O'Riordan August 27, 2016
News Daily News USPSTF: Not Enough Evidence to Recommend Routine Lipid Screening in Children and Adolescents Michael O'Riordan August 09, 2016
News Features Requiem for a Heavyweight: Big Brand Statin Era Comes to a Close as Crestor Heads Off-Patent Michael O'Riordan May 03, 2016
News Daily News No More Niacin, Fibrate Combinations With Statins: FDA Michael O'Riordan April 19, 2016
News Industry News Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union September 28, 2015
News Industry News New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology August 20, 2015
News Daily News Zero Calcium Score Provides 15-Year Mortality ‘Warranty’ for Asymptomatic Patients August 06, 2015
News Industry News Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia July 24, 2015
News Industry News European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol July 21, 2015
News Industry News Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease June 05, 2015
News Daily News Michigan Registry Study Finds Pre-PCI Statin Use Not Associated with Better Outcomes April 21, 2014